Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy

Soumerai Jacob D.; Ni Ai; Darif Mohamed; Londhe Anil; Xing Guan; Mun Yong; Kay Neil E.; Shanafelt Tait D.; Chaffee Kari G.; Furman Richard R.; Hillmen Peter; Sharman Jeff; Seymour John F.; Chanan-Khan Asher A.; Byrd John C.; Jones Jeffrey A.; Ferrante Lucille A.; Dreiling Lyndah K.; Mobasher Mehrdad; Stark Thomas; Reddy Vijay; Howes Angela J.; James Danelle; Bhargava Pankaj; Zelenetz Andrew D.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy

【24h】

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy

机译：复发/难治性慢性淋巴细胞白血病患者的整体存活风险模型：伊布洛替尼，伊雷利尼布，威尼替肽或化疗症的患者验证

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2018年第novaelatreatmentappr期|共5页
作者
Soumerai Jacob D.; Ni Ai; Darif Mohamed; Londhe Anil; Xing Guan; Mun Yong; Kay Neil E.; Shanafelt Tait D.; Chaffee Kari G.; Furman Richard R.; Hillmen Peter; Sharman Jeff; Seymour John F.; Chanan-Khan Asher A.; Byrd John C.; Jones Jeffrey A.; Ferrante Lucille A.; Dreiling Lyndah K.; Mobasher Mehrdad; Stark Thomas; Reddy Vijay; Howes Angela J.; James Danelle; Bhargava Pankaj; Zelenetz Andrew D.;
展开▼
作者单位

Mem Sloan Kettering Canc Ctr Lymphoma Serv 1275 York Ave New York NY 10021 USA;

Mem Sloan Kettering Canc Ctr Dept Epidemiol &

Biostat New York NY 10021 USA;

Janssen Pharmaceut Inc Horsham PA USA;

Janssen Pharmaceut Inc Horsham PA USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Genentech Inc San Francisco CA 94080 USA;

Mayo Clin Div Hematol Rochester MN USA;

Stanford Univ Stanford CA 94305 USA;

Mayo Clin Dept Hlth Sci Res Rochester MN USA;

Weill Cornell Med Div Hematol &

Oncol New York NY USA;

St James Univ Hosp Leeds W Yorkshire England;

US Oncol Res Willamette Valley Canc Inst Eugene OR USA;

Peter MacCallum Canc Ctr Melbourne Vic Australia;

Mayo Clin Jacksonville FL 32224 USA;

Ohio State Univ Columbus OH 43210 USA;

Ohio State Univ Columbus OH 43210 USA;

Janssen Pharmaceut Inc Horsham PA USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Pharmacyclics LLC Sunnyvale CA USA;

Janssen Pharmaceut Inc Horsham PA USA;

Pharmacyclics LLC Sunnyvale CA USA;

Gilead Sci Inc 353 Lakeside Dr Foster City CA 94404 USA;

Mem Sloan Kettering Canc Ctr Lymphoma Serv 1275 York Ave New York NY 10021 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy [J] . Soumerai Jacob D., Ni Ai, Darif Mohamed, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：复发/难治性慢性淋巴细胞白血病患者的整体存活风险模型：伊布洛替尼，伊雷利尼布，威尼替肽或化疗症的患者验证
2. Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) [J] . Brown Jennifer R., Davids Matthew S., Chang Julie, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：在伊布勒替尼 - 幼稚患者的复发/耐火（R / R）慢性淋巴细胞白血病（CLL）后伊布勒替尼氏菌治疗后伊布洛替尼治疗疗法的结果
3. Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study [J] . Greil Richard, Fraser Graeme, Leber Brian, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：尿嘧啶（SB）在尿嘧啶复发/难治（R / R）慢性淋巴细胞白血病（CLL）中的IBR-NAIVIVE患者治疗后Ibrutinib（SEN）治疗的疗效和安全性：来自Murano研究的患者的随访
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Kinase Targeting Therapies in Chronic Lymphocytic Leukemia: Mechanisms of Acquired Ibrutinib Resistance and the Pre-Clinical Development of OSU-T315. [D] . Liu, Ta-Ming. 2014

机译：激酶靶向疗法在慢性淋巴细胞性白血病中：获得性依鲁替尼耐药性的机制和OSU-T315的临床前开发。
6. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group [O] . Maria Winqvist, Anna Asklid, PO Andersson, 2016

机译：依鲁替尼在复发或难治性慢性淋巴细胞性白血病患者中的真实结果：来自以同情心使用计划治疗的95位连续患者的数据。瑞典慢性淋巴细胞白血病小组的一项研究
7. A MRD-GUIDED APPROACH FOR THE COMBINATION OF IBRUTINIB TO VENETOCLAX IN RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (IMPROVE STUDY) [O] . P. Ghia, L. Scarfò, M. Coscia, 2017

机译：一种MRD引导方法，易于慢性淋巴细胞白血病复发/难治性患者在复发/难治性患者中的组合方法（改进研究）

Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy

著录项

相似文献

相关主题

期刊订阅